CLINICAL TRIALS PROFILE FOR LOSMAPIMOD
✉ Email this page to a colleague
Clinical Trials for Losmapimod
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00633022 ↗ | A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging | Completed | GlaxoSmithKline | Phase 2 | This study is being conducted to assess the potential anti-inflammatory effects of a 3-month treatment with GW856553, on the inflammatory activity within the aorta and carotid plaques, as assessed by FDG-PET/CT. |
NCT01039961 ↗ | PK Study of IV Formulation of GW856553 | Completed | GlaxoSmithKline | Phase 1 | The purpose of this study is to evaluate the safety of an IV infusion of GW856553 in healthy volunteers. |
NCT01218126 ↗ | Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstr | Completed | GlaxoSmithKline | Phase 2 | Randomised, double-blind, parallel-group, multi-centre study evaluating three doses of losmapimod (2.5mg, 7.5 mg and 15 mg) twice daily (BID) versus placebo on exercise tolerance. Eligible subjects will be randomised to treatment after a one-week run-in period. The duration of the treatment period is 24 weeks. An estimated 1000 subjects will be screened to reach the target enrolment of approximately 600 randomised subjects. |
NCT01541852 ↗ | Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen. | Completed | GlaxoSmithKline | Phase 2 | The main purpose of this study is to determine the effect of Losmapimod on blood vessels in patients with Chronic Obstructive Pulmonary Disease (COPD). Although COPD is a lung disease, it is also associated with an increased risk of cardiovascular disease (e.g. heart attacks and stroke). The investigators believe that this is a result of inflammation within the body, which damages the lining (endothelium) and walls of blood vessels. These changes can promote the development of fatty deposits within the walls of arteries (atherosclerosis) which can rupture and block arteries causing damage. |
NCT01541852 ↗ | Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen. | Completed | Royal Brompton & Harefield NHS Foundation Trust | Phase 2 | The main purpose of this study is to determine the effect of Losmapimod on blood vessels in patients with Chronic Obstructive Pulmonary Disease (COPD). Although COPD is a lung disease, it is also associated with an increased risk of cardiovascular disease (e.g. heart attacks and stroke). The investigators believe that this is a result of inflammation within the body, which damages the lining (endothelium) and walls of blood vessels. These changes can promote the development of fatty deposits within the walls of arteries (atherosclerosis) which can rupture and block arteries causing damage. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Losmapimod
Condition Name
Clinical Trial Locations for Losmapimod
Trials by Country
Clinical Trial Progress for Losmapimod
Clinical Trial Phase
Clinical Trial Sponsors for Losmapimod
Sponsor Name